nach oben

Annals of Nuclear Medicine

Erschienen in:

01.02.2011 | Review Article

Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review

verfasst von: Lutfun Nisa, Giordano Savelli, Raffaele Giubbini

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Treatment of somatostatin receptor-positive tumors with radiolabeled somatostatin analog is a promising option. Several phase I and phase II studies done at a few centers around the world reported encouraging results with [⁹⁰Y-DOTA-Tyr³]-octreotide (DOTATOC) and/or [¹⁷⁷Lu-DOTA-Tyr³-Thr⁸]-octreotate (DOTATATE). The current article is a selective review of patients who were treated mainly with ⁹⁰Y-DOTATOC after failure with conventional therapy. The aim is to provide an updated comprehensive evaluation of the overall effectiveness of ⁹⁰Y-DOTATOC therapy in patients with somatostatin-positive tumors. Review of several studies revealed an objective response rate ranging from 20 to 28% for all neuroendocrine tumors (NET)s. For gastroenteropancreatic-NET (GEP-NET), the response rate was found to be consistently better in the range 28–38%. Overall, the cumulative response rate was found to be 24%. An important issue in peptide receptor radionuclide therapy (PRRT) is the dose–response relationship and finding the correct dose of ⁹⁰Y-DOTATOC that will achieve an optimum tumor kill. Nephrotoxicity was common but could be minimized by taking adequate renal protective measures. In conclusion, PRRT remains a good option in patients with inoperable and/or metastatic NETs particularly of GEP origin. Over a decade of experience with ⁹⁰Y-DOTATOC proves that it is still an effective tool for the treatment of large infiltrative NETs with achievement of objective radiological responses in nearly a quarter and disease stabilization in more than half the patients studied so far.

Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683–9.CrossRefPubMed

Khanna G, Bushnell D, O’Dorisio MS. Utility of radiolabelled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist. 2008;13:382–9.CrossRefPubMed

Öberg K. Management of neuroendocrine tumors. Ann Oncol. 2004;15:iv293–8.

Bieligk S, Jaffe BM. Islet cell tumors of the pancreas. Surg Clin North Am. 1995;75:1025–40.PubMed

Öberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol. 1998;10:58–65.CrossRefPubMed

Higgins GA, Recant L, Fischman AB. The glucagonoma: surgically curable diabetes. Am J Surg. 1979;137:142–8.CrossRefPubMed

Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagons producing islet cell tumors. Am J Gastroenterol. 1981;76:125–31.PubMed

Raut C, Kulke M, Glickman J, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006;43:383–450.CrossRefPubMed

De Herder WW, Hofland LJ, Van Der Lely AJ, Lambert SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2003;10:451–8.CrossRefPubMed

10.

De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumor therapy: current status and future directions. Eur J Nucl Med. 2003;30:463–9.CrossRef

11.

McCarthy KE, Woltering EA, Antony LB. In situ radiotherapy with ¹¹¹In-pentreotide State of the art and perspectives. Q J Nucl Med. 2000;44:88–95.PubMed

12.

Antony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium 111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–32.CrossRef

13.

Béhé M, Heppeler A, Maecke HR. New somatostatin analogs for SPET and PET. Eur J Nucl Med 1996;23:1144 (abstract).

14.

Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumors. Acta Oncol. 2007;46:723–34.CrossRefPubMed

15.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastro-enteropancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177LuDOTA(0), Tyr(3) octreotide. Eur J Nucl Med Mol Imaging. 2003;30:417–22.CrossRefPubMed

16.

Otte A, Jermann E, Béhé M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: A powerful new tool for receptor mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–6.PubMed

17.

Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Ytterium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–8.CrossRefPubMed

18.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATAC first clinical results. Eur J Nucl Med. 1999;26:1439–47.CrossRefPubMed

19.

Paganelli G, Zoboli S, Cremonesi M, Mäcke HR, Chinol M. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477–83.CrossRefPubMed

20.

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol. 2001;12:941–5.CrossRefPubMed

21.

Waldherr C, Schumacher T, Maecke HR, Schirp U, Forrer F, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq ⁹⁰Y-DOTATOC. J Nucl Med. 2002;43:610–6.PubMed

22.

Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor mediated radiotherapy with ⁹⁰Y-DOTA-D-Phe¹-Tyr³-octreotide. Eur J Nucl Med. 2001;28:426–34.CrossRefPubMed

23.

Paganelli G, Bodei L, Junak DH, Rocca P, Papi S, Sierra ML, et al. ⁹⁰Y-DOTA-D-Phe¹-Tyr³-octreotide in therapy of neuroendocrine malignancies. Biopolymers (Peptide Science). 2002;66:393–8.CrossRef

24.

Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with ⁹⁰Y-DOTA-Dphe¹-Tyr³- octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 2002;32:141–7.CrossRefPubMed

25.

Valkema R, Jamar F, Bakker WH, Norenberg J, Smith C, Stolz B, et al. Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487;OCTREOTHERTM) peptide receptor radionuclide therapy (PRRT): preliminary results of a phase-I study (abstract OS-248). Eur J Nucl Med. 2001;28(Suppl):1025P.

26.

Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med. 2003;30:207–16.CrossRef

27.

Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with ⁹⁰Y-[DOTA]⁰-Tyr3-Octreotide (⁹⁰Y-DOTATOC] in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2004;31:1038–46.CrossRefPubMed

28.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [⁹⁰Y-DOTA⁰ Tyr³] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–56.CrossRefPubMed

29.

Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors. J Surg. 2006;140(6):968–77.CrossRef

30.

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with ⁹⁰Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703–8.PubMed

31.

Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334–40.PubMed

32.

Muros MA, Varsavsky M, Rozas PI, Valdivia J, Delgado JR, Forrer F, et al. Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clin Transl Oncol. 2009;11:48–53.CrossRefPubMed

33.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman APW, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–40.CrossRefPubMed

34.

Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA 0, Tyr3] octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18(4):619–25.CrossRefPubMed

35.

Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2005;32:511–2.CrossRefPubMed

36.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99S–106S.PubMed

37.

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56 (epub 22 Apr 2008; erratum in Eur J Nucl Med Mol Imaging. 2008;35:1928).

38.

Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y]-DOTA-D-Phel-Tyr3-octeotide([90Y]-SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med. 1998;25:668–74.CrossRefPubMed

39.

Gotthardt M, Dijkgraaf I, Boerman OC, Oyen WJG. Nuclear Medicine imaging and therapy of neuroendocrine tumors. Cancer Imaging. 2006;6:S178–84.CrossRefPubMed

40.

Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using ⁹⁰Yttrium-DOTATOC, an Yttrium-labeled somatostatin analogue: a pilot trial. Lung Cancer. 2004;45:365–71.CrossRefPubMed

41.

Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, et al. Response to [⁹⁰Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13:6696–702.CrossRefPubMed

42.

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMed

43.

Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62((Suppl 1)):69–72.CrossRefPubMed

44.

Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with ⁹⁰Y-DOTATOC. Eur J Nucl Med. 2001;28:1552–4.CrossRefPubMed

45.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46:83S–91S.PubMed

46.

Heute D, Kostron H, Guggenberg EV, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC. J Nucl Med. 2010;51:397–400.CrossRefPubMed

47.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed

48.

Kwekkeboom DJ, Bakker WH, Kooj PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0, Tyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.CrossRefPubMed

Titel: Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review
verfasst von: Lutfun Nisa
Giordano Savelli
Raffaele Giubbini
Publikationsdatum: 01.02.2011
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 2/2011
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-010-0444-0

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

F18-FDG-PET/CT thyroid incidentalomas and their benign or malignant nature: a critical and debated issue

Acknowledgements to Reviewers

Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?

Comparison of 99mTc-labeled PR81 and its F(ab′)2 fragments as radioimmunoscintigraphy agents for breast cancer imaging

Deep-inspiration breath-hold PET/CT versus free breathing PET/CT and respiratory gating PET for reference: evaluation in 95 patients with lung cancer

Clinical usefulness of a collimator distance dependent resolution recovery in myocardial perfusion SPECT: a clinical report from a single institute